Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease

202255 citationsJournal Article

Authors

Good health and well-being

Published in: Atherosclerosis

Volume 349, pp. 240-247

Field-Weighted Citation Impact: 11.99